Cardiovascular Center of Excellence Sees Success With Translational Research Event
In order to support the translational research mission of the UC College of Medicine and the Cardiovascular Center of Excellence (CvCOE) as well as to bring both cardiac caregivers and basic researchers together for potential collaboration, the CvCOE held a Translational Research Day, titled "Bridging the Lab and the Clinic," on Tuesday, Oct. 11.
About 150 attendeeshalf scientists, half clinicianswere present for the days events, which included three main information sessions, highlighting various cardiovascular-related research projects, and ended with a poster presentation which included research from 48 young trainees and a wine and cheese reception.
Neal Weintraub, MD, Mabel Stearns Stonehill Chair of Cardiology, chief of the division of cardiovascular diseases and co-director of the CvCOE along with Litsa Kranias, PhD, says the goal of the event was to encourage interaction between clinicians and basic scientists in the field. The outcome was successful, he says.
"A number of rousing talks were delivered by our scientists and clinical faculty that highlighted the cutting-edge work within cardiovascular sciences at UC, he says. "I saw many clinicians asking questions of basic scientists work and vice versa. I think that there was consistent interest among colleagues and a true meeting of the minds.
"We expect to do this annually and expand our reach to other departments. This event truly served its purpose of getting people to communicate and hopefully collaborate more closely in the future.
Four prizestwo first-place ties and two second-place tieswere awarded for the poster presentations. Winners were:
· First Place: Bin Yu, PhD, in the lab of Meifeng Xu, PhD, associate professor of pathology and laboratory medicine, and Nathan Robbins in the lab of Jack Rubinstein, MD, assistant professor in the division of cardiovascular diseases and a UC Health cardiologist. Both received $300 and a certificate.
· Second Place: Stela Florea, PhD, in the lab of Litsa Kranias, PhD, professor of pharmacology and cell biophysics, and Xiaowei Zhang, PhD, in the lab of Guo-Chang Fan, PhD, assistant professor of pharmacology and cell biophysics. Both received $200 and a certificate.
"We had fantastic clinical and basic science talks, and the speakers generated a good amount of excitement and cross-talk focused on the translation of our research findings to meet clinical needs, says Keith Jones, PhD, professor in the department of pharmacology and cell biophysics. "Reciprocally, the basic scientists learned of the clinical challenges, and clinical needs were identified that we hope will provoke new translational science projects.
"All in all, this meeting exemplifies the goals of the CVCoEto support basic, translational and clinical research and to enhance interactions between basic scientists and clinicians in order to maximize the potential for development of new therapeutics from our research. In the long run, this is the path to development of new therapies that will allow the clinicians to provide better care."
Cardiovascular Center of Excellence Translational Research Day Poster Presentation
Cardiovascular Center of Excellence Translational Research Day Poster Presentation
Cardiovascular Center of Excellence Translational Research Day
Related Stories
UC invests in the next generation of graduate leaders through fellowships focused on mentorship and research
September 3, 2026
The Next Lives Here Presidential Fellowship supports the recruitment of top doctoral students through competitive funding, mentorship and professional development.
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.